title: Life after ibrutinib? A new unmet need in CLL.
abstract: In this issue of Blood, Jain et al reported on the poor outcomes of patients with chronic lymphocytic leukemia (CLL) after the discontinuation of ibrutinib.
authors: MOFFITT CANCER CENTER.
authors: Javier
authors: http://orcid.org/0000-0003-3170-9648
authors: J
authors: Pinilla-Ibarz
authors: MOFFITT CANCER CENTER.
authors: Julio C
authors: JC
authors: Chavez
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000188:drug therapy*; D010880:Piperidines; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D028761:Withholding Treatment
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine